Weiss Ratings assumed coverage on shares of Carlsmed (NASDAQ:CARL – Get Free Report) in a report released on Thursday,Weiss Ratings reports. The brokerage set a “sell (e)” rating on the stock.
Carlsmed Stock Performance
Carlsmed stock opened at $13.55 on Thursday. Carlsmed has a 52-week low of $11.81 and a 52-week high of $16.20.
Carlsmed (NASDAQ:CARL – Get Free Report) last released its quarterly earnings data on Thursday, August 28th. The company reported ($1.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.52) by $0.05. The business had revenue of $12.08 million during the quarter, compared to analyst estimates of $11.98 million.
About Carlsmed
We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).
See Also
- Five stocks we like better than Carlsmed
- NYSE Stocks Give Investors a Variety of Quality Options
- This AI Chip Giant Could Be the Market’s Next Big Winner
- What is an Earnings Surprise?
- Broadcom Inks OpenAI Deal: Why It’s A Huge Win for AVGO Stock
- Best Energy Stocks – Energy Stocks to Buy Now
- Institutions Are Fueling CrowdStrike’s Next Leg Higher
Receive News & Ratings for Carlsmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carlsmed and related companies with MarketBeat.com's FREE daily email newsletter.
